Elan Shares Climb on $3.25B Biogen's Tysabri Deal
Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
Is Political Risk Premium Being Priced Into U.S. Assets?
32:50 - UniCredit Research Head of Global FX Vasileios Gkionakis discusses the political risk premium associated with President Trump, the dollar and unemployment. He speaks with on "Bloomberg Markets.” (Source: Bloomberg)